Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfiz­er, Mer­ck and — as we found out Fri­day morn­ing — Ver­tex to the grow­ing list of phar­ma gi­ants hit­ting the pause but­ton on a range of clin­i­cal tri­als. But not every­one in R&D is get­ting a red light.

Ver­tex says that it’s do­ing its best to keep work­ing its pipeline strat­e­gy, com­ing up with a plan “to en­able vir­tu­al clin­ic vis­its and home de­liv­ery of study drug to en­sure study con­ti­nu­ity and med­ical mon­i­tor­ing, and to fa­cil­i­tate study pro­ce­dures.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER